From a regulatory standpoint, this isn't just interesting it's a problem. Agencies evaluate drug products. They don't regulate psychotherapy. If a meaningful, inseparable portion of the treatment effect comes from the therapeutic container rather than the molecule, then defining the independent variable becomes genuinely complicated and your development program needs to address that directly.
-
2 Записей
-
1 Фото
-
0 Видео
-
Проживает в USA
-
Из USA
-
Читают 1 человек
© 2026 Soocian
Russian
Недавние обновления
-
The Development Alignment GapWhy Clinical Development Programs Fail Before FDA Ever Reviews the Data A Strategic Perspective on Evidence Generation, Regulatory Alignment, and Development Success Denis Katz, MD Founder, Salience Clinical LLC Executive Summary Over the course of my career, I've participated in and advised development programs across pharmaceuticals, biologics, regenerative medicine, diagnostics, neuroscience...0 Комментарии 0 Поделились 206 Просмотры 0 предпросмотрВойдите, чтобы отмечать, делиться и комментировать!
-
0 Комментарии 0 Поделились 95 Просмотры 0 предпросмотр
Больше